Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

“We are incredibly proud to introduce the only Health Canada-approved treatment for FA ... Canada approves Biogen’s Skyclarys ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

Ataxia Treatment Market, trends, and advancements in neurological disorder treatments. Discover growth drivers, key players, and forecasts up to 2035 ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

Lexeo Therapeutics (LXEO) announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia ...

A West Annapolis family has turned two life-altering diagnoses into more than $1 million for research toward finding a cure ...

Treatment with a 150 mg daily oral dose of omaveloxolone over 48 weeks in the study resulted in a significant improvement in the symptoms of Friedreich’s ataxia – measured using the mFARS ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 9.71%, which has investors questioning if this is right time to buy ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...